Analysis for MO
- 📈 Growth — 13/30
- 💰 Profitability — 17/20
- 🏦 Financial Health — 6/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 8/10
Summary:
📈 Growth & Financial Trajectory
From 2024 Q1 to 2025 Q4, revenue rose modestly from approximately $5.58B to $5.85B (about 4.9%), while net income declined from about $2.13B to $1.12B. The 8-quarter sequence shows a mid-2025 peak in revenue near $6.10B–$6.07B with solid operating income, but 2025 Q4 suffered margin pressure. On average, gross margins hovered around 60% and operating margins averaged about 44%, signaling durable profitability but with quarterly volatility.
💰 Margins & Cash Flow
Across the eight quarters, gross margin remained strong (roughly 58–63%), while operating margin averaged ~44% due to fluctuating quarterly leverage. The spread between gross and operating performance narrowed in Q4 2025 as revenue declined. Cash flow from operating activities was robust in most periods (roughly $2.0B–$3.3B per quarter), with investing cash flow modestly negative and financing activity often negative, yielding mixed net cash flow.
🛡️ Balance Sheet & Liquidity
Total Assets ≈ $35.0B vs Liabilities ≈ $38.5B, with Equity around -$3.5B in latest quarter. Current assets ≈ $5.9B and current liabilities ≈ $9.2B (current ratio < 1.0), and long-term debt ≈ $25.7B. The company generates cash from operations, but negative equity and a lean liquidity cushion raise solvency concerns despite ongoing cash generation.
⚠️ Key Drivers & Risks
- Drivers: Pricing power and stable brand positioning in tobacco; recurring cash flow support from core volumes.
- Risks: Structural negative equity and high leverage; regulatory/regulatory exposure and earnings volatility may pressure valuations and liquidity.